Primary Biliary Cholongitis Market Research Report 2030 by DelveInsight

 Primary biliary cholangitis (PBC), previously known as Primary Biliary Cirrhosis is a chronic, or long lasting, progressive liver disorder that mostly affects women and usually appears during middle age. PBC leads to inflammation and scarring of the small bile ducts.

DelveInsight's "Primary Biliary Cholongitis Market Insights, Epidemiology and Market Forecast 2030" report delivers an in-depth understanding of the Primary Biliary Cholongitis , historical and forecasted epidemiology as well as the Primary Biliary Cholongitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. 

Geography Covered

·         The United States

·         EU5 (Germany, France, Italy, Spain, and the United Kingdom)

·         Japan

Study Period: 2017-2030

View full report: https://www.delveinsight.com/report-store/primary-biliary-cholongitis-market

Primary Biliary Cholongitis Disease Understanding and Treatment Algorithm

When PBC is very severe, it can lead to yellow discoloration of the skin (jaundice). If PBC is untreated, it can lead to cirrhosis, or scarring of the entire liver, which can lead to liver failure. PBC is divided into four stages, with stage 1 being early disease, where this is no significant scarring, to stage 4, or which is defined by cirrhosis.

Although the exact cause of PBC is unknown, it is thought that it is likely due to a combination of factors such as autoimmune, genetic, and environmental factors.

The most common symptoms of PBC are:

o    Fatigue

o    Pruritus (itchiness)

o    Jaundice

PBC affects mostly women, but more men are now being diagnosed. The disorder usually becomes apparent during middle age, initially affecting most individuals between the ages of 45 to 65 years.

The DelveInsight Primary Biliary Cholongitis market report gives a thorough understanding of the Primary Biliary Cholongitis by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment. 

Primary Biliary Cholongitis Epidemiology  

The Primary Biliary Cholongitis epidemiology division provide insights about historical and current Primary Biliary Cholongitis patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.  

Key Findings

·         According to the National Organization for Rare Disorders (NORD), it has been estimated that PBC is one of the most common autoimmune diseases, affecting nearly 1 in 1000 women over the age of 40.

·         According to “Orphanet”, Affected individuals are usually in their fifth to seventh decades of life at time of diagnosis, and 90% are women. Annual incidence is estimated at between 1/1,430,000 and 1/20,400 inhabitants and prevalence at between 1/150,000 and 1/1,063 inhabitants (depending on age and sex).

The disease epidemiology covered in the report provides historical as well as forecasted Primary Biliary Cholongitis epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030. 

Request for sample pages: https://www.delveinsight.com/sample-request/primary-biliary-cholongitis-market

Primary Biliary Cholongitis Drug Chapters

The dynamics of Primary Biliary Cholangitis market is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the diseases, incremental healthcare spending across the world, and also expects the launch of emerging therapies during the forecast period of 2020–2030.      

Drug chapter segment of the Primary Biliary Cholongitis report encloses the detailed analysis of Primary Biliary Cholongitis marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Primary Biliary Cholongitis clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Primary Biliary Cholongitis Market Outlook

Primary biliary cholangitis (often referred to as primary biliary cirrhosis) is a type of liver disease that can get gradually worse over time. Without treatment, it may eventually lead to liver failure. Diagnosis can be typically established by the triad: antimitochondrial antibodies (AMA) in serum, cholestatic indices and liver histology diagnostic or compatible with PBC. If AMA testing is negative, then a patient would need a liver biopsy to confirm the diagnosis of PBC, since a number of diseases can cause a high ALP.

Currently, there is no cure for PBC. The main aim in the management of PBC is to reverse injury from bile duct inflammation, improve the symptoms, slow down progression of the disease, improve liver biochemistry and improve long-term consequences of chronic cholestasis, such as pruritus, fatigue, osteoporosis and fat-soluble vitamin deficiencies.

The Primary Biliary Cholongitis market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Primary Biliary Cholongitis market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology. 

According to DelveInsight, Primary Biliary Cholongitis market in 7MM is expected to change in the study period 2017-2030.

Download report: https://www.delveinsight.com/report-store/primary-biliary-cholongitis-market

Download sample pages: https://www.delveinsight.com/sample-request/primary-biliary-cholongitis-market